Zacks Investment Research upgraded shares of Homology Medicines (NASDAQ:FIXX) from a hold rating to a buy rating in a research report released on Thursday. The brokerage currently has $19.00 target price on the stock.

According to Zacks, “Homology Medicines Inc. is a genetic medicines company. Its platform offers human hematopoietic stem cell derived adeno-associated virus vectors to treat disease-causing mutations through gene correction, insertion and knockout. Homology Medicines Inc. is based in BEDFORD MA. “

A number of other analysts also recently commented on the company. Bank of America initiated coverage on Homology Medicines in a research report on Monday, April 23rd. They set a buy rating and a $27.00 target price on the stock. BTIG Research initiated coverage on Homology Medicines in a research report on Tuesday, April 24th. They set a buy rating and a $35.00 target price on the stock. Cowen initiated coverage on Homology Medicines in a research report on Monday, April 23rd. They set an outperform rating on the stock. Finally, Evercore ISI initiated coverage on Homology Medicines in a research report on Monday, April 23rd. They set an outperform rating and a $30.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of Buy and an average target price of $27.75.

FIXX traded down $0.97 during trading on Thursday, reaching $16.38. 594 shares of the stock were exchanged, compared to its average volume of 142,507. Homology Medicines has a 1 year low of $15.22 and a 1 year high of $24.40.

Homology Medicines (NASDAQ:FIXX) last posted its earnings results on Monday, August 13th. The company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.02). The business had revenue of $0.93 million during the quarter. equities analysts anticipate that Homology Medicines will post -1.74 earnings per share for the current year.

A number of institutional investors have recently added to or reduced their stakes in the stock. FMR LLC increased its stake in Homology Medicines by 12.9% in the second quarter. FMR LLC now owns 3,359,715 shares of the company’s stock valued at $67,192,000 after purchasing an additional 384,818 shares during the last quarter. Temasek Holdings Private Ltd acquired a new position in Homology Medicines in the first quarter valued at $60,219,000. Vivo Capital LLC increased its stake in Homology Medicines by 21.6% in the second quarter. Vivo Capital LLC now owns 1,409,742 shares of the company’s stock valued at $28,759,000 after purchasing an additional 250,000 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in Homology Medicines during the first quarter worth about $22,772,000. Finally, Rock Springs Capital Management LP acquired a new stake in Homology Medicines during the first quarter worth about $10,753,000. Hedge funds and other institutional investors own 48.17% of the company’s stock.

Homology Medicines Company Profile

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

See Also: What is a closed-end mutual fund (CEF)?

Get a free copy of the Zacks research report on Homology Medicines (FIXX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.